Infinity Pharmaceuticals to Present at Upcoming BIO CEO & Investor Conference
February 11 2021 - 8:25AM
Business Wire
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage
biotechnology company developing eganelisib, a potentially
first-in-class, oral, immuno-oncology macrophage reprogramming
therapeutic which addresses a fundamental biologic mechanism of
immune suppression in cancer, today announced that management will
be presenting at the BIO CEO & Investor Conference taking place
February 16-18. Presentations details are below:
BIO CEO & Investor Conference
Presentation Details:
Date:
February 16 – 18
Presentation:
Available on demand starting February 16th
at 10am EST
The link for the presentation will be available at www.infi.com.
About Infinity and Eganelisib
Infinity is an innovative biopharmaceutical company dedicated to
developing novel medicines for people with cancer. Infinity is
advancing eganelisib, a potentially first-in-class, oral,
immuno-oncology macrophage reprogramming therapeutic which
addresses a fundamental biologic mechanism of immune suppression in
cancer, in multiple clinical studies. MARIO-275 is a Phase 2,
randomized, placebo-controlled study of eganelisib combined with
Opdivo in I/O naïve urothelial cancer. MARIO-3 is the first
eganelisib combination study in front-line advanced cancer patients
and is evaluating eganelisib in combination with Tecentriq® and
Abraxane® in front-line TNBC and in combination with Tecentriq and
Avastin® in front-line RCC. In collaboration with Arcus
Biosciences, Infinity is evaluating a checkpoint inhibitor-free,
novel combination regimen of eganelisib plus etrumadenant (dual
adenosine receptor antagonist) plus Doxil® in advanced TNBC
patients. With these studies Infinity is evaluating eganelisib in
the anti-PD-1 refractory, I/O-naïve, and front-line and second line
settings. For more information on Infinity, please refer to
Infinity's website at www.infi.com.
Opdivo® is a registered trademark of Bristol Myers Squibb.
Tecentriq® is a registered trademark of Genentech, Inc. Abraxane®
is a registered trademark of Abraxis BioScience, LLC. Avastin® is a
registered trademark of Genentech, Inc. Doxil® is a registered
trademark of Baxter Healthcare Corporation.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210211005569/en/
Investor Relations Contact: Ashley Robinson LifeSci
Advisors, LLC 617-775-5956
Infinity Pharmaceuticals (NASDAQ:INFI)
Historical Stock Chart
From Apr 2024 to May 2024
Infinity Pharmaceuticals (NASDAQ:INFI)
Historical Stock Chart
From May 2023 to May 2024